Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.74), $0.07 worse than the analyst estimate of ($0.67).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.